NASDAQ:TENX

Tenax Therapeutics Q1 2025 Earnings Results & Report

Tenax Therapeutics logo
$1.42 -0.06 (-4.05%)
Closing price 04:00 PM Eastern
Extended Trading
$1.46 +0.04 (+2.46%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tenax Therapeutics beat analyst earnings expectations in its Q1 2025 results, released May 14, 2025. The company reported EPS of -$0.28 versus the -$0.48 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
12:30 PM ET

Tenax Therapeutics EPS Results

Actual EPS
-$0.28
Consensus EPS
-$0.48
Beat/Miss
Beat by +$0.20
One Year Ago EPS
N/A
EPS Beat Rate
8 of last 8 quarters

Tenax Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tenax Therapeutics Q1 2025 Earnings FAQ

Tenax Therapeutics (NASDAQ:TENX) reported earnings of -$0.28 per share for Q1 2025, beating the consensus estimate of -$0.48. The report was announced on Wednesday, May 14, 2025.

Tenax Therapeutics Earnings Headlines

Today's free pick (on me)
Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th.tc pixel
See More Tenax Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tenax Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tenax Therapeutics and other key companies, straight to your email.

About Tenax Therapeutics

Tenax Therapeutics (NASDAQ:TENX) is a clinical-stage biopharmaceutical company focused on developing treatments for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), a condition involving elevated pressure in the lung’s blood vessels and impaired heart function.

The company’s lead program is levosimendan, a drug being developed in different formulations for PH-HFpEF. Tenax has described its development program as including oral, intravenous and subcutaneous formulations. Levosimendan is approved for certain heart-failure uses in some countries, but Tenax is studying it for a different indication.

Tenax Therapeutics is based in Morrisville, North Carolina, and its work centers on clinical development rather than marketing an established commercial product.

View Tenax Therapeutics Profile